M. Slaoui
About
M. Slaoui is a scholar working on Epidemiology, Immunology and Molecular Biology.
According to data from OpenAlex, M. Slaoui has authored 51 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 19 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in M. Slaoui's work include T-cell and B-cell Immunology (11 papers), Herpesvirus Infections and Treatments (9 papers) and Hepatitis B Virus Studies (8 papers). M. Slaoui is often cited by papers focused on T-cell and B-cell Immunology (11 papers), Herpesvirus Infections and Treatments (9 papers) and Hepatitis B Virus Studies (8 papers). M. Slaoui collaborates with scholars based in United States, Belgium and Germany. M. Slaoui's co-authors include D. Gray Heppner, Urszula Krzych, Lawrence R. Stanberry, David I. Bernstein, Matthew J. Hepburn, Nathalie Garçon, Pierre Vandepapelière, W. Ripley Ballou, Kent E. Kester and Joe Cohen and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.
In The Last Decade
M. Slaoui
51 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| M. Slaoui United States | 26 | 1.6k | 1.1k | 773 | 726 | 550 | 51 | 3.2k | ||
| Louis Fries United States | 37 | 1.8k 1.2× | 1.1k 0.9× | 500 0.6× | 568 0.8× | 1.1k 2.0× | 77 | 3.5k | ||
| Sanjay Gurunathan United States | 28 | 1.8k 1.2× | 1.9k 1.7× | 932 1.2× | 1.1k 1.5× | 1.0k 1.9× | 46 | 4.4k | ||
| Ian J. Amanna United States | 22 | 896 0.6× | 1.3k 1.1× | 408 0.5× | 716 1.0× | 960 1.7× | 42 | 3.0k | ||
| Fabiana Falugi Italy | 20 | 1.4k 0.9× | 479 0.4× | 791 1.0× | 988 1.4× | 950 1.7× | 25 | 3.5k | ||
| Julie Furze United Kingdom | 23 | 1.3k 0.8× | 737 0.7× | 212 0.3× | 464 0.6× | 783 1.4× | 27 | 2.2k | ||
| Galina V. Yamshchikov United States | 25 | 587 0.4× | 1.8k 1.6× | 359 0.5× | 1.1k 1.5× | 735 1.3× | 38 | 3.0k | ||
| Michel Klein Canada | 30 | 1.2k 0.7× | 947 0.8× | 151 0.2× | 929 1.3× | 779 1.4× | 77 | 3.8k | ||
| J S Remington United States | 36 | 2.5k 1.6× | 640 0.6× | 485 0.6× | 458 0.6× | 506 0.9× | 78 | 3.9k | ||
| Walter R. Weiss United States | 28 | 561 0.4× | 1.9k 1.6× | 1.6k 2.1× | 1.2k 1.7× | 468 0.9× | 52 | 3.7k | ||
| Niranjan Y. Sardesai United States | 36 | 966 0.6× | 1.6k 1.4× | 519 0.7× | 1.2k 1.7× | 1.0k 1.8× | 120 | 3.9k |
Countries citing papers authored by M. Slaoui
Since
Specialization
Citations
This map shows the geographic impact of M. Slaoui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Slaoui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Slaoui more than expected).
Fields of papers citing papers by M. Slaoui
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by M. Slaoui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Slaoui. The network helps show where M. Slaoui may publish in the future.
Co-authorship network of co-authors of M. Slaoui
This figure shows the co-authorship network connecting the top 25 collaborators of M. Slaoui. A scholar is included among the top collaborators of M. Slaoui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Slaoui. M. Slaoui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cam, Yann Le, et al.. (2014). Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives. Orphanet Journal of Rare Diseases. 9(1). 20–20.
2.
Fontanges, Thierry, François Bailly, Eric Trépo, et al.. (2008). Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique. 32(10). 858–865.
3.
Repessé, Yohann, M. Slaoui, Philippe Gautier, et al.. (2007). Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. Journal of Thrombosis and Haemostasis. 5(7). 1469–1476.
4.
Bourne, Nigel, Fernando Bravo, M Francotte, et al.. (2003). Herpes Simplex Virus (HSV) Type 2 Glycoprotein D Subunit Vaccines and Protection against Genital HSV‐1 or HSV‐2 Disease in Guinea Pigs. The Journal of Infectious Diseases. 187(4). 542–549.
5.
Stanberry, Lawrence R., Spotswood L. Spruance, Anthony L. Cunningham, et al.. (2002). Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes. New England Journal of Medicine. 347(21). 1652–1661.
6.
Prince, Gregory A., et al.. (2001). Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine. 19(15-16). 2048–2054.
7.
Ambrosch, F, G Wiedermann, Michael Kundi, et al.. (2000). A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 18(20). 2095–2101.
8.
Stoute, José A., M. Slaoui, D. Gray Heppner, et al.. (1997). A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalaria. New England Journal of Medicine. 336(2). 86–91.
9.
Neuzil, Kathleen M., Joyce E. Johnson, Yi‐Wei Tang, et al.. (1997). Adjuvants influence the quantitative and qualitative immune response in BALBc mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine. 15(5). 525–532.
10.
Rosenthal, Susan L., Lawrence R. Stanberry, Frank M. Biro, et al.. (1997). Seroprevalence of Herpes Simplex Virus Types 1 and 2 and Cytomegalovirus in Adolescents. Clinical Infectious Diseases. 24(2). 135–139.
11.
Keadle, Tammie L., Keith A. Laycock, Judith Kelvin Miller, et al.. (1997). Efficacy of a Recombinant Glycoprotein D Subunit Vaccine on the Development of Primary and Recurrent Ocular Infection with Herpes Simplex Virus Type 1 in Mice. The Journal of Infectious Diseases. 176(2). 331–338.
12.
Zepp, Fred, H. J. Schmitt, Achim Kaufhold, et al.. (1996). Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. European Journal of Pediatrics. 156(1). 18–24.
13.
Bratcher, Denise F., N. K. Bourne, Mark R. Schleiss, et al.. (1995). Effect of Passive Antibody on Congenital Cytomegalovirus Infection in Guinea Pigs. The Journal of Infectious Diseases. 172(4). 944–950.
14.
Gaito, John, et al.. (1994). Paracetamol potentiates isaxonine toxicity in vitro. Toxicology Letters. 73(3). 167–173.
15.
Slaoui, M., et al.. (1993). Efficacy of the Herpes Simplex Virus Types 1 and 2 Mutant Viruses to Confer Protection against Zosteriform Spread in Mice. Viral Immunology. 6(1). 35–42.
16.
Bruck, Claudine, M S Co, M. Slaoui, et al.. (1986). Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen.. Proceedings of the National Academy of Sciences. 83(17). 6578–6582.
17.
Léo, Oberdan, M. Slaoui, Jacqueline Marvel, et al.. (1985). Idiotypic analysis of polyclonal and monoclonal anti-p-azophenylarsonate antibodies of BALB/c mice expressing the major cross-reactive idiotype of the A/J strain.. The Journal of Immunology. 134(3). 1734–1739.
18.
Monroe, John G., et al.. (1985). Genetic and biological characterization of a T suppressor cell induced by anti-idiotypic antibody.. The Journal of Immunology. 135(3). 1589–1597.
19.
Slaoui, M., et al.. (1984). Complete amino acid sequence of heavy chain variable regions derived from two monoclonal anti-p-azophenylarsonate antibodies of BALB/c mice expressing the major cross-reactive idiotype of the A/J strain.. The Journal of Experimental Medicine. 160(4). 1070–1086.
20.
Slaoui, M., Oberdan Léo, Jacqueline Marvel, et al.. (1984). Idiotypic analysis of potential and available repertoires in the arsonate system.. The Journal of Experimental Medicine. 160(1). 1–11.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Louis Fries Breakdown of academic impact, for papers by Sanjay Gurunathan Breakdown of academic impact, for papers by Ian J. Amanna Breakdown of academic impact, for papers by Fabiana Falugi Breakdown of academic impact, for papers by Julie Furze Breakdown of academic impact, for papers by Galina V. Yamshchikov Breakdown of academic impact, for papers by Michel Klein Breakdown of academic impact, for papers by J S Remington Breakdown of academic impact, for papers by Walter R. Weiss Breakdown of academic impact, for papers by Niranjan Y. Sardesai